Skip to main content
Top
Published in: Pituitary 3/2014

01-06-2014

Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study

Authors: Xiao-Bing Jiang, Cui-Ling Li, Dong-Sheng He, Zhi-Gang Mao, Dong-Hong Liu, Xiang Fan, Bin Hu, Yong-Hong Zhu, Hai-Jun Wang

Published in: Pituitary | Issue 3/2014

Login to get access

Abstract

Hyperprolactinemia is associated with endothelial dysfunction and atherogenic risk factors, but carotid intima media thickness (IMT) has not been studied in hyperprolactinemic patients. To determine whether untreated hyperprolactinemia contributes to increased carotid IMT. Thirty-one prolactinoma patients and 60 healthy controls were respectively studied. Participants underwent hormone evaluation. Anthropometric parameters (body mass index and blood pressure), inflammatory markers (high-sensitivity C-reactive protein and fibrinogen), serum glucose, insulin, lipid and apolipoprotein profiles were also determined. Endothelial function measured as the flow-mediated dilation (FMD) of a brachial artery and carotid IMT were evaluated using high-resolution ultrasonography. Multivariate linear regression analysis was applied to identify independent determinants of FMD and carotid IMT. Triglycerides, homeostasis model assessment of insulin resistance, apolipoprotein (apo)B/apoA-I ratio, high-sensitivity C-reactive protein (hsCRP) and fibrinogen were significantly higher, while apoA-I was significantly lower in patients with prolactinomas than in the controls. Meanwhile, decreased FMD and increased carotid IMT were observed in hyperprolactinemic group. Serum prolactin was positively correlated with triglycerides, apoB/apoA-I ratio, hypogonadal, hsCRP and fibrinogen (P < 0.05), but inversely associated with apoA-I and HDL-C (P ≤ 0.001). Moreover, prolactin was found negatively correlated with FMD (r = −0.576, P < 0.0001), and positively correlated with mean carotid IMT (r = 0.652, P < 0.0001). Multivariate regression analysis revealed that prolactin determined, independent of traditional risk factors, FMD (B = −0.589, 95 % confidence interval (CI) −2.525 to −0.804, P = 0.001) and mean carotid IMT (B = 0.527, 95 % CI 0.027–0.069, P < 0.0001). Hyperprolactinemia may be involved in the preclinical increase in carotid IMT, directly or by promoting atherogenic factors, including insulin resistance, low-grade inflammation and endothelial dysfunction. Additional studies are warranted to confirm our findings and explore the mechanisms underlying prolactin-associated early atherosclerosis.
Literature
1.
go back to reference Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769–4775PubMedCrossRef Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769–4775PubMedCrossRef
2.
go back to reference Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288PubMedCrossRef Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288PubMedCrossRef
4.
go back to reference Dos SSC, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR (2011) BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 19:800–805CrossRef Dos SSC, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR (2011) BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 19:800–805CrossRef
5.
go back to reference Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL (2011) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14:199–207PubMedCrossRef Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL (2011) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14:199–207PubMedCrossRef
6.
go back to reference Schmid C, Goede DL, Hauser RS, Brandle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 136:254–258PubMed Schmid C, Goede DL, Hauser RS, Brandle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 136:254–258PubMed
7.
go back to reference Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370 Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370
8.
go back to reference Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147:77–84PubMedCrossRef Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147:77–84PubMedCrossRef
9.
go back to reference de Assuncao ARL, Campos SM, Miranda PA, Bizzi MF, Sales DAP, Giannetti AV, Ribeiro-Oliveira A (2012) Prolactinoma: a condition associated with hypoadiponectinemia. Horm Metab Res 44:832–838CrossRef de Assuncao ARL, Campos SM, Miranda PA, Bizzi MF, Sales DAP, Giannetti AV, Ribeiro-Oliveira A (2012) Prolactinoma: a condition associated with hypoadiponectinemia. Horm Metab Res 44:832–838CrossRef
10.
go back to reference Jiang XB, He DS, Mao ZG, Fan X, Lei N, Hu B, Song BB, Zhu YH, Wang HJ (2013) BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort. Tumour Biol 34:1171–1176PubMedCrossRef Jiang XB, He DS, Mao ZG, Fan X, Lei N, Hu B, Song BB, Zhu YH, Wang HJ (2013) BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort. Tumour Biol 34:1171–1176PubMedCrossRef
11.
go back to reference Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G, Akalin S (2003) Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 149:187–193PubMedCrossRef Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G, Akalin S (2003) Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 149:187–193PubMedCrossRef
12.
go back to reference Merkle CJ, Schuler LA, Schaeffer RJ, Gribbon JM, Montgomery DW (2000) Structural and functional effects of high prolactin levels on injured endothelial cells: evidence for an endothelial prolactin receptor. Endocrine 13:37–46PubMedCrossRef Merkle CJ, Schuler LA, Schaeffer RJ, Gribbon JM, Montgomery DW (2000) Structural and functional effects of high prolactin levels on injured endothelial cells: evidence for an endothelial prolactin receptor. Endocrine 13:37–46PubMedCrossRef
13.
go back to reference Sauro MD, Zorn NE (1991) Prolactin induces proliferation of vascular smooth muscle cells through a protein kinase C-dependent mechanism. J Cell Physiol 148:133–138PubMedCrossRef Sauro MD, Zorn NE (1991) Prolactin induces proliferation of vascular smooth muscle cells through a protein kinase C-dependent mechanism. J Cell Physiol 148:133–138PubMedCrossRef
14.
go back to reference Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP (2009) Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54:98–105PubMedCrossRef Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP (2009) Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54:98–105PubMedCrossRef
15.
go back to reference Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM, van der Loos CM, Claessen N, Teeling P, Kastelein JJ, Hamann J, Goffin V, von der Thusen JH (2011) The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? J Endocrinol 208:107–117PubMedCrossRef Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM, van der Loos CM, Claessen N, Teeling P, Kastelein JJ, Hamann J, Goffin V, von der Thusen JH (2011) The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? J Endocrinol 208:107–117PubMedCrossRef
16.
go back to reference Carrero JJ, Kyriazis J, Sonmez A, Tzanakis I, Qureshi AR, Stenvinkel P, Saglam M, Stylianou K, Yaman H, Taslipinar A (2012) Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 7:207–215PubMedCentralPubMedCrossRef Carrero JJ, Kyriazis J, Sonmez A, Tzanakis I, Qureshi AR, Stenvinkel P, Saglam M, Stylianou K, Yaman H, Taslipinar A (2012) Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 7:207–215PubMedCentralPubMedCrossRef
17.
go back to reference Koivistoinen T, Virtanen M, Hutri-Kahonen N, Lehtimaki T, Jula A, Juonala M, Moilanen L, Aatola H, Hyttinen J, Viikari JS (2012) Arterial pulse wave velocity in relation to carotid intima-media thickness, brachial flow-mediated dilation and carotid artery distensibility: the cardiovascular risk in Young Finns Study and the Health 2000 Survey. Atherosclerosis 220:387–393PubMedCrossRef Koivistoinen T, Virtanen M, Hutri-Kahonen N, Lehtimaki T, Jula A, Juonala M, Moilanen L, Aatola H, Hyttinen J, Viikari JS (2012) Arterial pulse wave velocity in relation to carotid intima-media thickness, brachial flow-mediated dilation and carotid artery distensibility: the cardiovascular risk in Young Finns Study and the Health 2000 Survey. Atherosclerosis 220:387–393PubMedCrossRef
18.
go back to reference Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMedCrossRef Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMedCrossRef
19.
go back to reference Skipworth RJ, Moses AG, Sangster K, Sturgeon CM, Voss AC, Fallon MT, Anderson RA, Ross JA, Fearon KC (2011) Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer 19:391–401PubMedCrossRef Skipworth RJ, Moses AG, Sangster K, Sturgeon CM, Voss AC, Fallon MT, Anderson RA, Ross JA, Fearon KC (2011) Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer 19:391–401PubMedCrossRef
20.
go back to reference Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, Schoenfeld DA, Hayden DL, Wright ME, Woodburn CJ, Klibanski A (2001) Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) 54:183–188CrossRef Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, Schoenfeld DA, Hayden DL, Wright ME, Woodburn CJ, Klibanski A (2001) Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) 54:183–188CrossRef
21.
go back to reference Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP (2009) Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54:98–105PubMedCrossRef Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP (2009) Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54:98–105PubMedCrossRef
22.
go back to reference Stumpe KO, Kolloch R, Higuchi M, Kruck F, Vetter H (1977) Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine control. Lancet 2:211–214PubMedCrossRef Stumpe KO, Kolloch R, Higuchi M, Kruck F, Vetter H (1977) Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine control. Lancet 2:211–214PubMedCrossRef
23.
go back to reference Montes DOP, Macotela Y, Nava G, Lopez-Barrera F, de la Escalera GM, Clapp C (2005) Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells. Lab Invest 85:633–642CrossRef Montes DOP, Macotela Y, Nava G, Lopez-Barrera F, de la Escalera GM, Clapp C (2005) Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells. Lab Invest 85:633–642CrossRef
24.
25.
go back to reference Ochoa-Amaya JE, Malucelli BE, Cruz-Casallas PE, Nasello AG, Felicio LF, Carvalho-Freitas MI (2011) Dual effects of hyperprolactinemia on carrageenan-induced inflammatory paw edema in rats. Neuroimmunomodulat 18:245–253CrossRef Ochoa-Amaya JE, Malucelli BE, Cruz-Casallas PE, Nasello AG, Felicio LF, Carvalho-Freitas MI (2011) Dual effects of hyperprolactinemia on carrageenan-induced inflammatory paw edema in rats. Neuroimmunomodulat 18:245–253CrossRef
26.
go back to reference Reuwer AQ, Sondermeijer BM, Battjes S, van Zijderveld R, Stuijver DJ, Bisschop PH, Twickler MT, Meijers JC, Schlingemann RO, Stroes ES (2012) Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study. Pituitary 15:472–481PubMedCentralPubMedCrossRef Reuwer AQ, Sondermeijer BM, Battjes S, van Zijderveld R, Stuijver DJ, Bisschop PH, Twickler MT, Meijers JC, Schlingemann RO, Stroes ES (2012) Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study. Pituitary 15:472–481PubMedCentralPubMedCrossRef
27.
go back to reference Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR (2006) Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 17:110–116PubMedCrossRef Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR (2006) Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 17:110–116PubMedCrossRef
28.
go back to reference Johnston DG, Alberti KG, Nattrass M, Burrin JM, Blesa-Malpica G, Hall K, Hall R (1980) Hyperinsulinaemia in hyperprolactinaemic women. Clin Endocrinol (Oxf) 13:361–368CrossRef Johnston DG, Alberti KG, Nattrass M, Burrin JM, Blesa-Malpica G, Hall K, Hall R (1980) Hyperinsulinaemia in hyperprolactinaemic women. Clin Endocrinol (Oxf) 13:361–368CrossRef
29.
30.
go back to reference Dahlen EM, Lanne T, Engvall J, Lindstrom T, Grodzinsky E, Nystrom FH, Ostgren CJ (2009) Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type 2 diabetes. Diabet Med 26:384–390PubMedCrossRef Dahlen EM, Lanne T, Engvall J, Lindstrom T, Grodzinsky E, Nystrom FH, Ostgren CJ (2009) Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type 2 diabetes. Diabet Med 26:384–390PubMedCrossRef
Metadata
Title
Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study
Authors
Xiao-Bing Jiang
Cui-Ling Li
Dong-Sheng He
Zhi-Gang Mao
Dong-Hong Liu
Xiang Fan
Bin Hu
Yong-Hong Zhu
Hai-Jun Wang
Publication date
01-06-2014
Publisher
Springer US
Published in
Pituitary / Issue 3/2014
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-013-0495-z

Other articles of this Issue 3/2014

Pituitary 3/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.